Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1976 1
1977 1
1981 1
1985 1
1998 1
1999 1
2000 1
2001 3
2002 2
2003 2
2004 3
2005 3
2006 3
2007 1
2008 2
2009 2
2010 3
2011 2
2012 4
2013 2
2014 2
2015 3
2016 3
2017 8
2018 4
2019 3
2020 5
2021 2
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study.
Savas P, Lo LL, Luen SJ, Blackley EF, Callahan J, Moodie K, van Geelen CT, Ko YA, Weng CF, Wein L, Silva MJ, Bujak AZ, Yeung MM, Ftouni S, Hicks RJ, Francis PA, Lee CK, Dawson SJ, Loi S. Savas P, et al. Among authors: moodie k. Cancer Discov. 2022 Sep 2;12(9):2058-2073. doi: 10.1158/2159-8290.CD-21-1696. Cancer Discov. 2022. PMID: 35771551 Clinical Trial.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Buteau JP, et al. Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16. Lancet Oncol. 2022. PMID: 36261050 Clinical Trial.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30. Lancet Oncol. 2024. PMID: 38043558 Clinical Trial.
Time to learn something new.
Moodie KL. Moodie KL. Lab Anim (NY). 2020 Mar;49(3):57. doi: 10.1038/s41684-020-0487-3. Lab Anim (NY). 2020. PMID: 32099138 No abstract available.
Detection of subclinical hemorrhage using electrical impedance: a porcine study.
Murphy EK, Klein SB, Hamlin A, Anderson JE, Minichiello JM, Lindqwister AL, Moodie KL, Wanken ZJ, Read JT, Borza VA, Elliott JT, Halter RJ, Vaze VS, Paradis NA. Murphy EK, et al. Among authors: moodie kl. Physiol Meas. 2022 May 25;43(5). doi: 10.1088/1361-6579/ac6cc6. Physiol Meas. 2022. PMID: 35508144
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Thorne H, Devereux L, Li J, Alsop K, Christie L, van Geelen CT, Burdett N, Pishas KI, Woodford N, Leditschke J, Izzath MHMA, Strachan K, Young G, Jaravaza RD, Madadin MS, Archer M, Glengarry J, Iles L, Rathnaweera A, Hampson C, Almazrooei K, Burke M, Bandara P, Ranson D, Saeedi E, McNally O, Mileshkin L, Hamilton A, Ananda S, Au-Yeung G, Antill Y, Sandhu S, Savas P, Francis PA, Luen S, Loi S, Jennens R, Scott C, Moodie K, Cummings M, Reid A, McCart Reed A, Bowtell D, Lakhani SR, Fox S. Thorne H, et al. Among authors: moodie k. Histopathology. 2023 Jul;83(1):91-103. doi: 10.1111/his.14906. Epub 2023 Mar 31. Histopathology. 2023. PMID: 36999648
Porcine-human glioma xenograft model. Immunosuppression and model reproducibility.
Hoopes PJ, Tavakkoli AD, Moodie KA, Maurer KJ, Meehan KR, Wallin DJ, Aulwes E, Duval KEA, Chen KL, -Burney MAC, Li C, Fan X, Evans LT, Paulsen KD. Hoopes PJ, et al. Among authors: moodie ka. Cancer Treat Res Commun. 2024;38:100789. doi: 10.1016/j.ctarc.2024.100789. Epub 2024 Jan 13. Cancer Treat Res Commun. 2024. PMID: 38262125 Free PMC article.
Treatment of Canine Oral Melanoma with Nanotechnology-Based Immunotherapy and Radiation.
Hoopes PJ, Wagner RJ, Duval K, Kang K, Gladstone DJ, Moodie KL, Crary-Burney M, Ariaspulido H, Veliz FA, Steinmetz NF, Fiering SN. Hoopes PJ, et al. Among authors: moodie kl. Mol Pharm. 2018 Sep 4;15(9):3717-3722. doi: 10.1021/acs.molpharmaceut.8b00126. Epub 2018 Apr 12. Mol Pharm. 2018. PMID: 29613803 Free PMC article.
Micro computed tomography for vascular exploration.
Zagorchev L, Oses P, Zhuang ZW, Moodie K, Mulligan-Kehoe MJ, Simons M, Couffinhal T. Zagorchev L, et al. Among authors: moodie k. J Angiogenes Res. 2010 Mar 5;2:7. doi: 10.1186/2040-2384-2-7. J Angiogenes Res. 2010. PMID: 20298533 Free PMC article.
73 results